<DOC>
	<DOC>NCT00568022</DOC>
	<brief_summary>The purpose of this study is to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and recommended Phase II dose of ixabepilone in combination with capecitabine in Japanese participants with metastatic breast cancer.</brief_summary>
	<brief_title>A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Women ≥ 20 years Histologically or cytologically confirmed diagnosis of adenocarcinoma originating in the breast Number of prior chemotherapy lines of treatment in the metastatic setting ≥3</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>